Icagen, a biopharmaceutical firm developing drugs that treat by modulating ion channels, priced its offering of 5 million share at the $8 downwardly revised price estimate on Thursday. The company lowered its estimated price to $8 from a range of $10 to $12 earlier in the day. Joint book runners on the deal were JP Morgan and UBS Investment Bank. The stock is expected to trade on the NASDAQ under the ticker ICGN.
